296 related articles for article (PubMed ID: 19366798)
1. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
2. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
3. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
[TBL] [Abstract][Full Text] [Related]
4. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
5. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
[TBL] [Abstract][Full Text] [Related]
7. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
Gu Y; Patterson AV; Atwell GJ; Chernikova SB; Brown JM; Thompson LH; Wilson WR
Mol Cancer Ther; 2009 Jun; 8(6):1714-23. PubMed ID: 19509245
[TBL] [Abstract][Full Text] [Related]
8. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Guise CP; Abbattista MR; Tipparaju SR; Lambie NK; Su J; Li D; Wilson WR; Dachs GU; Patterson AV
Mol Pharmacol; 2012 Jan; 81(1):31-40. PubMed ID: 21984255
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
10. Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study.
Gu Y; Wilson WR
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3181-6. PubMed ID: 19709934
[TBL] [Abstract][Full Text] [Related]
11. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
Gu Y; Tingle MD; Wilson WR
J Pharmacol Exp Ther; 2011 Jun; 337(3):692-702. PubMed ID: 21427202
[TBL] [Abstract][Full Text] [Related]
12. Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104A.
Stornetta A; Deng KK; Danielli S; Liyanage HDS; Sturla SJ; Wilson WR; Gu Y
Biochem Pharmacol; 2018 Aug; 154():64-74. PubMed ID: 29630868
[TBL] [Abstract][Full Text] [Related]
13. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
Patel K; Choy SS; Hicks KO; Melink TJ; Holford NH; Wilson WR
Cancer Chemother Pharmacol; 2011 May; 67(5):1145-55. PubMed ID: 20683596
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans.
Gu Y; Atwell GJ; Wilson WR
Drug Metab Dispos; 2010 Mar; 38(3):498-508. PubMed ID: 20019245
[TBL] [Abstract][Full Text] [Related]
15. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.
Beall HD; Mulcahy RT; Siegel D; Traver RD; Gibson NW; Ross D
Cancer Res; 1994 Jun; 54(12):3196-201. PubMed ID: 8205540
[TBL] [Abstract][Full Text] [Related]
17. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
18. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
[TBL] [Abstract][Full Text] [Related]
19. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.
Bizanek R; Chowdary D; Arai H; Kasai M; Hughes CS; Sartorelli AC; Rockwell S; Tomasz M
Cancer Res; 1993 Nov; 53(21):5127-34. PubMed ID: 7693331
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry.
Patel K; Lewiston D; Gu Y; Hicks KO; Wilson WR
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):302-11. PubMed ID: 17644498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]